TL;DR — The ASCO 2026 Annual Meeting runs May 29 – June 2, 2026 at McCormick Place in Chicago. Roughly 45,000 attendees from 130+ countries make it the largest clinical oncology meeting in the world, with a heavy academic and NCI-designated cancer center skew. Booth space alone runs $80–$110/sqft, and credible all-in presence typically lands between $250K and $1.5M+ for pharma and $75K–$200K for device and diagnostics exhibitors. Win it by treating ASCO as a media moment rather than a lead-capture show: time data releases against the abstract embargo, lock in KOL engagements 90+ days out, run a Friday pre-show investigator dinner, and build a follow-up plan that respects committee-driven buying cycles at academic cancer centers.

What ASCO Is — and Why Chicago 2026 Matters

The American Society of Clinical Oncology Annual Meeting is the single most important clinical and commercial moment in oncology. ASCO 2026 lands at McCormick Place in Chicago from May 29 through June 2, and for most pharma, biotech, and oncology device companies it is both the largest individual conference investment of the year and the venue where the practice-changing data of the year is presented. Late-breaking abstracts at ASCO move stock prices, change NCCN guidelines, and reset competitive narratives across every major tumor type.

For marketing teams, that compounding effect is what makes ASCO different from a typical clinical meeting. The booth is only a fraction of the program. The real work happens in coordinated abstract releases, investor and analyst meetings, KOL roundtables, satellite symposia, sponsored education, social and earned media pickup, and a pre-/post-show outreach engine that often runs for 60 days on either side of the meeting itself.

Chicago in late May has its own logistical reality. McCormick Place is the largest convention center in North America, the Annual Meeting consumes the full North and South halls, and hotel inventory inside the official ASCO block disappears within hours of opening. Teams that wait until February to start planning ASCO almost always pay double for staff hotels, miss prime booth real estate, and lose the KOL calendar slots that drive meaningful pipeline at the show.

ASCO 2026: The Numbers You Need

The pricing math is brutal at first glance, but the comparison that matters is cost-per-qualified-decision-maker. Roughly 30,000 of the on-site attendees are practicing oncologists or oncology pharmacists with prescribing or formulary input, and a meaningful slice of those are concentrated at the 70+ NCI-designated cancer centers that drive disproportionate guideline adoption. No other oncology meeting puts that audience in one building. For a drug or device commercializing into solid tumor or hematologic indications, the question is not whether to exhibit at ASCO — it is how to make ASCO pay back against the entire calendar year of competitive activity.

Pre-ASCO Strategy: Treat It Like a Product Launch

ASCO is not a trade show. It is a clinical communications launch with a booth attached to it. Teams that plan ASCO as a booth-first event consistently underperform teams that plan ASCO as a 90-day integrated launch with the booth as one of seven workstreams.

Lock in abstract and data strategy by mid-February. If your company has accepted abstracts — especially late-breakers, oral presentations, or plenaries — the entire ASCO communications plan should be built around those data drops. Coordinate with regulatory, medical affairs, and investor relations on the embargo lift sequence, the press release timing, the analyst pre-briefs, and the social media handle-by-handle rollout. The biggest avoidable mistake at ASCO is good data buried by poor communications timing.

Build a KOL engagement calendar 90 days out. The 200–300 oncologists who drive the most opinion leadership across NCCN guidelines, trial enrollment, and peer-to-peer influence have their ASCO calendars locked by mid-April. If you want a 30-minute roundtable, a podcast taping, an advisory board seat, or a satellite symposium speaker slot from any of those KOLs, you book it in February. Our broader medical device KOL program management framework applies directly here, with the caveat that oncology KOL density and competition for time is unusually high.

Pre-show investigator and advisor dinners. The Friday evening before ASCO opens is the highest-leverage non-podium moment of the entire week. Top sites, KOLs, payers, and reference customers are in town but not yet pulled into the meeting itself. A well-curated 12–25 person investigator dinner on Friday produces more strategic value than three days of badge scans for most oncology commercial teams.

Target list discipline at the cancer center level. Build your named-account target list by NCI-designated and major regional academic cancer centers, with the specific decision-makers — division chiefs, P&T committee chairs, infusion pharmacy directors, radiation oncology chairs, GU/GI/breast/thoracic program leads — surfaced and prioritized. Most oncology product decisions are committee decisions, and walking into ASCO without committee-level intelligence is how you leave Chicago with badge scans instead of pipeline.

Booth Design and Messaging for an Oncology Audience

ASCO booth design is its own discipline. The audience is sophisticated, time-compressed, and walking past booths at a pace that gives you roughly five seconds to land a relevant claim. The booths that win the floor at ASCO consistently do four things well.

Lead with the indication and the patient. Generic "innovation in oncology" headlines lose to specific patient-level claims tied to a real tumor type, line of therapy, or clinical decision. The oncologist walking the floor wants to know in seconds whether your product is relevant to the patients they will see in clinic next Tuesday. Tumor type, line of therapy, biomarker status — those are the first three pieces of information your booth signage should communicate.

Build a data zone and a workflow zone. The data zone is for clinical and economic evidence presented with appropriate citation discipline (this matters at ASCO; sloppy or unsourced claims will be flagged by the audience). The workflow zone is for how your product slots into infusion pharmacy, biomarker testing, multidisciplinary tumor boards, or radiation planning. Most oncology buyers care equally about both, but they need the booth architecture to separate the conversations cleanly. Our medical conference booth design playbook covers zone layouts in more detail.

Engineer for the multidisciplinary buyer. Modern oncology decisions involve medical oncology, surgical oncology, radiation oncology, pathology, pharmacy, and increasingly molecular tumor boards and supportive care. A booth that talks only to medical oncologists leaves money on the table. Build distinct content pathways — and ideally distinct rep specializations — for each persona that influences your buying decision.

Mind the regulated copy reality. ASCO booths attract intense regulatory and competitive scrutiny. Marketing claims need to match your label, your published data, and your fair balance posture. We've written more on the oncology device marketing claim-discipline reality and how to balance commercial energy against regulatory exposure on the floor.

Earned Media, Social, and the ASCO News Cycle

For a few days in late May, oncology is on the front page of the financial and trade press. STAT, Endpoints News, FiercePharma, BioPharma Dive, Reuters Health, and Bloomberg all assign dedicated ASCO desks. Sell-side analysts publish daily ASCO recap notes that move stocks. Twitter/X #ASCO26 — and increasingly LinkedIn and Bluesky — produce the real-time interpretation of new data that shapes prescribing patterns weeks before published manuscripts catch up.

The companies that win this earned media moment are not the ones with the biggest booths. They are the ones with the best-prepared spokespeople, the cleanest data narrative, and a media engagement plan that runs from Thursday pre-show through Tuesday post-show. Investigator spokespeople need media training specifically for ASCO — the questions are sharper, the embargo rules are stricter, and a single off-message quote in a STAT story can undo months of commercial preparation.

Social media at ASCO has its own ecosystem. The "Oncology Twitter" community — many of whom are also active on LinkedIn — drives a remarkable share of how new data is interpreted in the days and weeks after the meeting. Your medical affairs and communications teams should have a coordinated social plan, with embargo-aware tweets and posts queued, KOL-mention strategy in place, and a fast-response capability for unexpected data interpretations from competitors or analysts.

On-Site Tactics: Symposia, Roundtables, and Booth Conversations

The on-site week at ASCO breaks into roughly four parallel programs you should be running simultaneously: the booth, satellite symposia and sponsored education, KOL and investigator engagements, and investor/analyst meetings. Each one has its own staffing, scheduling, and content needs.

Satellite symposia and product theaters. ASCO restricts on-site commercial education, but adjacent venues (typically hotel ballrooms within walking distance of McCormick Place) host satellite symposia, product theaters, and medical affairs roundtables. These are the highest-converting on-site activities for most pharma and device teams when programmed well. Lock in the venue, the speakers, and the topic 6 months before the meeting. Promote attendance through pre-show email, sales rep outreach, and on-site signage. A well-executed satellite symposium can produce more qualified pipeline than a week of booth foot traffic.

Booth conversations should be triaged. Tier 1 leads (oncologist from a named target account, KOL, formulary decision-maker) get a senior MSL or rep, a same-day calendar invite for a follow-up call, and a hand-off to the named-account team within 48 hours. Tier 2 leads (qualified oncologist outside the target list) enter a structured medical affairs nurture. Tier 3 leads (general attendees, residents/fellows, international attendees outside your commercial geographies) get a single product overview email. Mixing these populations into a single drip campaign wastes the leads worth real money.

Investor and analyst meetings. ASCO is also one of the most important investor moments of the year for oncology-focused public companies. The Sunday and Monday investor breakfasts, banker dinners, and 1:1 analyst meetings often run from 6:30 AM to 9:00 PM. Investor relations should run this track independently of the marketing booth team, but commercial and medical affairs leaders should be available for select meetings to reinforce the commercial story behind the data.

Post-ASCO Follow-Up: Respecting Committee-Driven Decisions

The most common ASCO follow-up mistake is treating leads like a community-practice pipeline. Academic and major regional cancer centers buy by committee. A medical oncologist who signaled interest in your booth is one input into a P&T, biosimilar, formulary, or capital committee decision that may take 6–18 months to close. Your follow-up cadence has to respect that reality without losing the lead to a faster competitor.

Build the post-show plan around named accounts, not individual leads. Within five business days, your named-account team should have a consolidated view of every interaction your company had with each target cancer center during the meeting — booth visits, symposium attendance, KOL engagements, satellite event attendance, and social media engagement. That account-level intelligence is what enables a credible follow-up email from your VP of medical affairs or your division head three weeks after the show, when the committee starts forming its position.

For lower-priority leads outside the named-account list, a structured medical affairs and educational nurture is the right answer. Our post-conference follow-up playbook covers cadence and segmentation. Pair that with the pre-show outreach approach in our pre-conference email campaigns guide to run a coordinated 90-day pre-/post-ASCO motion rather than a one-week booth push.

Common Mistakes Vendors Make at ASCO

Underspending on KOL engagement and overspending on booth fabrication. A six-figure booth with no investigator dinners, no advisory board, and no satellite symposium will be out-converted by a smaller booth paired with a serious KOL engagement program every single year. Spend the marginal dollar on the people who shape opinion, not on the carpet.

Treating ASCO like a generic lead-gen show. Badge-scan-and-drip campaigns destroy the credibility of oncology brands. The audience is too sophisticated and too small for that approach. Build the program around content, education, and named-account engagement, and treat lead capture as a secondary output.

Ignoring the international attendee base. Roughly a third of ASCO attendees travel from outside the U.S. If your product has ex-U.S. commercial plans, your booth, your symposia, and your follow-up should reflect that — multilingual print, EU/APAC labeled-indication content, and regional commercial leaders staffed at the booth at predictable hours.

Poor coordination across medical, commercial, and IR. The three functions that should be most tightly integrated at ASCO often run as parallel silos. Medical affairs schedules KOL meetings that conflict with commercial product theaters. IR books analyst meetings during the abstract presentation. Commercial sends reps into booth shifts that overlap with their own satellite symposium. A single ASCO program manager with authority across all three functions is the single highest-leverage organizational investment you can make.

Walking away from regional follow-on opportunities. ASCO Annual is the main event, but ASCO GI, ASCO GU, ASCO Breast, ASCO Quality Care, and the various tumor-type ASCO meetings throughout the year produce real pipeline for vendors with focused indications. Companies that compound their Annual investment with strategic presence at the symposia outperform companies that treat ASCO Annual as a one-and-done.

Should You Exhibit at ASCO in 2026?

Yes, if you sell oncology drugs, biosimilars, radiation oncology equipment, surgical oncology platforms, biopsy and tissue acquisition systems, molecular diagnostics and liquid biopsy, clinical decision support, oncology informatics, or patient services that interact with academic cancer centers. ASCO is the single highest-leverage clinical and commercial moment of the year for those categories, and the cost of not being present is competitive narrative loss that compounds across the rest of the calendar.

Maybe, if your buyer is the community oncology practice manager or infusion clinic administrator. Community Oncology Alliance, ASCO Quality Care Symposium, and state oncology society meetings are often higher-ROI for that audience. ASCO Annual can still be relevant if you have data to present or a thought-leadership play, but a $200K+ commitment for community-oncology lead gen specifically usually does not clear ROI.

If you're trying to model whether your ASCO program will pay back, build the math the way our team does for clients: estimate the all-in cost including booth, satellite symposia, KOL engagement, travel, staffing, and pre-/post-show outreach. Divide by your average net-of-rebate annual revenue per academic center adoption. Ask whether 4–8 new academic cancer center adoptions in the next 12–18 months would justify the spend. For most oncology-focused commercial teams the answer is unambiguously yes — but only if the pre- and post-show motion is built with the discipline of a product launch. Our broader medical conference marketing ROI framework walks through the underlying model.